DanCann Pharma A/S Secures 10-Year Financing Loan-Agreement with 12-months Conversion Option and Warrants
COPENHAGEN, Denmark, 02 June 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has secured a financing agreement with Nordic Growth Opportunities 2 (the “Investor”), according to which the Company will receive up to DKK 18.9 million over the next 12 months and potentially additional proceeds if warrants are exercised by the Investor. The agreement is a 10-year financing loan agreement with 12 months conversion option and including warrants. The agreement is furthermore subject